JP2024507540A5 - - Google Patents
Info
- Publication number
- JP2024507540A5 JP2024507540A5 JP2023550601A JP2023550601A JP2024507540A5 JP 2024507540 A5 JP2024507540 A5 JP 2024507540A5 JP 2023550601 A JP2023550601 A JP 2023550601A JP 2023550601 A JP2023550601 A JP 2023550601A JP 2024507540 A5 JP2024507540 A5 JP 2024507540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- sequence
- heavy chain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163153884P | 2021-02-25 | 2021-02-25 | |
| US63/153,884 | 2021-02-25 | ||
| PCT/US2022/018029 WO2022183074A2 (en) | 2021-02-25 | 2022-02-25 | Anti-psma antibodies and car-t structures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507540A JP2024507540A (ja) | 2024-02-20 |
| JP2024507540A5 true JP2024507540A5 (https=) | 2025-03-04 |
Family
ID=80819665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550601A Pending JP2024507540A (ja) | 2021-02-25 | 2022-02-25 | 抗ｐｓｍａ抗体及びｃａｒ－ｔ構造 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240226162A9 (https=) |
| EP (1) | EP4298130A2 (https=) |
| JP (1) | JP2024507540A (https=) |
| KR (1) | KR20230148828A (https=) |
| CN (1) | CN117500835A (https=) |
| AU (1) | AU2022226277A1 (https=) |
| CA (1) | CA3211138A1 (https=) |
| MX (1) | MX2023009874A (https=) |
| WO (1) | WO2022183074A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| WO2025183244A1 (ko) * | 2024-02-29 | 2025-09-04 | 주식회사 피비앱셀 | Psma에 대한 항체 및 그의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP3402825A1 (en) * | 2016-01-12 | 2018-11-21 | Crescendo Biologics Limited | Molecules that bind prostate specific membrane antigen (psma) |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| WO2020206330A1 (en) * | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
-
2022
- 2022-02-25 KR KR1020237031488A patent/KR20230148828A/ko active Pending
- 2022-02-25 JP JP2023550601A patent/JP2024507540A/ja active Pending
- 2022-02-25 CN CN202280016722.9A patent/CN117500835A/zh active Pending
- 2022-02-25 AU AU2022226277A patent/AU2022226277A1/en active Pending
- 2022-02-25 WO PCT/US2022/018029 patent/WO2022183074A2/en not_active Ceased
- 2022-02-25 US US18/547,665 patent/US20240226162A9/en active Pending
- 2022-02-25 MX MX2023009874A patent/MX2023009874A/es unknown
- 2022-02-25 EP EP22711728.0A patent/EP4298130A2/en active Pending
- 2022-02-25 CA CA3211138A patent/CA3211138A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507540A5 (https=) | ||
| JP2021530236A5 (https=) | ||
| KR102710963B1 (ko) | 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용 | |
| JP2022505445A5 (https=) | ||
| JP2022537931A5 (https=) | ||
| JP2022526595A5 (https=) | ||
| CN110396129B (zh) | 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用 | |
| JP2024508808A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| BR112020004543A2 (pt) | proteínas de ligação ativadas condicionalmente restritas | |
| TW202302631A (zh) | 可誘導性結合蛋白和使用方法 | |
| CN117285642A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| JP2014510084A (ja) | 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法 | |
| CN118063619A (zh) | 工程化的异源二聚体蛋白质 | |
| CN103687879A (zh) | 多价抗原结合fv分子 | |
| JP2020530777A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN116323671A (zh) | 具有增加的选择性的多靶向性双特异性抗原结合分子 | |
| JP2020536512A (ja) | タンパク性ヘテロ二量体及びその使用 | |
| KR20210107747A (ko) | 항체 융합 단백질, 이의 제조 방법 및 이의 적용 | |
| WO2022166728A1 (zh) | 双特异性抗体 | |
| JP2024507693A5 (https=) | ||
| JP2026510999A (ja) | Ｃｄ１９／ｃｄ３８多重特異性抗体 | |
| TWI906795B (zh) | 特異性結合Ｃｌａｕｄｉｎ １８.２的抗體及其製法和應用 | |
| WO2022194201A1 (zh) | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 | |
| CN117843788A (zh) | 一种抗gprc5d的抗体及其多特异性抗体和相关应用 |